Article amendments



Erratum

Early G2/M checkpoint failure as a molecular mechanism underlying etoposide-induced chromosomal aberrations

Shinichiro Nakada, Yoko Katsuki, Issei Imoto, Tetsuji Yokoyama, Masayuki Nagasawa, Johji Inazawa, and Shuki Mizutani

Original citation: J. Clin. Invest. 116:80-89 (2006). doi:10.1172/JCI25716.

Citation for this erratum: J. Clin. Invest. 116:2306-2307 (2006). doi:10.1172/JCI25716E1.

During the preparation of the manuscript, errors were introduced in the labels of Figure 3E and Figure 6A. The corrected figures are provided below.

We regret this error.




Figure 3

FISH analysis for chromosome 11. (**A**) Representative image of metaphase ATM-deficient fibroblasts hybridized with the CH11C probe (green) and MLL probes (green and red overlap). Chromosomes were stained by DAPI. The arrows indicate overlapping MLL signals. (**B**) Representative image of metaphase ATM-deficient fibroblasts hybridized with probes for whole chromosome 11 (red) and MLL (green and red overlap). (**C**) Flow diagram of the cell fractionation procedure. (**D**) Etoposide-treated postmitotic G1 phase ATM-deficient fibroblasts with 1 (upper panel) and 3 (lower panel) centromeric 11q23 signals. (**E**) Proportion of metaphase and postmitotic G1 phase cells with gain (red) and loss (blue) of CH11C (left) or centromeric 11q23 (right) probe signals. n > 250 for each. *Odds ratio (OR) for etoposide treatment. **P = 0.77 and $^{\dagger}P < 0.0001$, differences in OR between postmitotic G1 and metaphase cells when cells were hybridized with CH11C and centromeric 11q23 probes, respectively (P for interaction term of cell cycle phase × treatment by a logistic regression model). (**F**) Micronuclei containing centromeric 11q23 signals (arrows). Cells were hybridized with centromeric 11q23 probes. Original magnification of FISH images, ×600.






Figure 6

Chromosomal aberrations in a mixture of stable clones of ATM-deficient fibroblasts, which had executed mitosis under etoposide treatment. (A) Flow diagram for long-term culture procedure. (B, C, and E) Metaphase spreads hybridized with the CH11C probe (green) and MLL probes (green and red overlap). (B) One GM05849C-MD cell showing 4 CH11C signals and 2 pairs of MLL signals. (C) One GM05849C-ME1 cell showing 4 CH11C signals with only 1 of them bearing MLL signals. (D) Proportion of cells with gain and loss of CH11C or MLL signals. n = 300 for each. *OR for etoposide treatment. **P = 0.0002, difference in OR for interaction term of probe × treatment by a logistic regression model. (E) One GM05849C-ME1 cell with the *MLL* gene translocated to another chromosome. The inset is a magnified image of the enclosed area. (F) Percent of chromosomes negative for CH11C signal among those positive for MLL signals. Data were analyzed by multiple logistic regression. n = 400 for each. †P = 0.028 for interaction term of etoposide treatment × mitotic progression. Neither of the pairwise comparisons for etoposide treatment in asynchronous cells nor for mitotic progression in etoposide-untreated cells was statistically significant (P = 1.0). (G) Representative image of chromosome 11 translocation (arrow) in GM05849C-ME1 cells hybridized with chromosome 11 painting (red) and MLL probes (green and red overlap). (H and I) Abnormal *MLL* gene configuration. GM05849C-ME1 cells were hybridized with MLL probes. Chromosomal translocation of *MLL* BCR (H) and tandem duplication of the *MLL* gene (I). Original magnification for FISH images, ×600.